NVAS too short
Posted: May 23, 2024
- Novavax ($NVAX) recently closed a $1.2 billion deal with Sanofi, making them profitable for the first time ever - Novavax receives royalties on all vaccine sales, potentially increasing the deal's value - Short interest in Novavax stock was at 33% on April 30th - Author believes the Sanofi deal has not been fully priced in, and many short positions have not been closed - Fidelity is expected to update their info soon, potentially leading to forced selling of short positions.
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!